Peter Van Vlasselaer, Ph.D.
Executive Chairman of Amphivena
Peter has over 20 years of experience in the biotech industry. He was most recently the Founder, President and Chief Executive Officer of ARMO Biosciences, which shortly after its public offering (ARMO) was acquired by Eli Lilly. Before that he was President and Chief Executive Officer of iPierian (acquired by BMS), ARRESTO (acquired by Gilead) and AVIDIA (acquired by AMGEN). In addition to founding ARMO, Dr. Van Vlasselaer was the founder of ARRESTO, co-founder of TrueNorth (acquired by Bioverativ) and he was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He currently serves on the boards of BLADE Therapeutics, Comet Therapeutics and RGENIX. Dr. Van Vlasselaer has a degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He was a Post-Doctoral Fellow in the Division of Immunology and Rheumatology at Stanford University Medical School and DNAX Research Institute. Dr. Van Vlasselaer has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.
Before joining Qiming in 2017, Mr. McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008. From 2002 until late 2007, Mr. McDade served as Chief Executive Officer and a director of PDL Biopharma, an antibody-based biopharma located in Redwood City, CA, USA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mark was founder and a director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 to December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000 to join Signature. Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management and general management. Mr. McDade serves on the Board of directors of FivePrime Therapeutics (FPRX), Dermira (DERM) and Aimmune Therapeutics (AIMT), all publicly traded biotechs in the SF Bay Area. Mark received a BA from Dartmouth College and an MBA from the Harvard Business School.
Eric joined NanoDimension in 2008 and was the first employee of NanoDimension’s Silicon Valley office. He is focused on life sciences investments. Eric is currently board member of Emulate, SQZ Biotech, Serotiny, Amphivena and a board observer of Inscripta and Click Diagnostics. He previously observed on the board of ARMO (acquired by Lilly), Twist Bioscience (Nasdaq: TWST) and IonPath. Eric helped lead NanoDimension’s investments in Orca and Octant. Before joining NanoDimension, Eric was a consultant at Bain & Company in Zurich and San Francisco. While at Bain, Eric worked on strategy cases in healthcare, industrial goods and telecommunications and on the turn-around of an electrical component manufacturer. In addition, Eric spent eight months in Bain’s Private Equity Group. Eric has an MS.c. from the London School of Economics and a BS/BA from the University of Florida.
Luke Evnin, Ph.D.
Luke Evnin is managing director of MPM Capital, a venture firm dedicated to life sciences investing. Dr. Evnin co-founded MPM’s asset management business in 1997 to launch MPM’s first venture fund and established the San Francisco office for the firm in 1999. Previously, Dr. Evnin was at Accel Partners for over seven years including four as a General Partner. At Accel Partners, he was involved in biopharmaceutical, medical device and healthcare service companies for Accel’s funds III, IV and V. Dr. Evnin earned his Ph.D. in the Department of Biochemistry at the University of California-San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University. He serves on the External Advisory Board for QB3, the Advisory Board for Mission Bay Capital (the internal venture investment vehicle for QB3), the External Advisory Board for the Lewis Sigler Institute of Quantitative Genomics at Princeton, and is the Chairman of the Scleroderma Research Foundation.
Christian Richard is an SVP, Research at Tekla Capital Management LLC, an advisor for four healthcare-focused closed-end investment funds since March of 2015. Previously, Mr. Richard was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Mr. Richard spent five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a B.S. in Cellular and Molecular Biology from Purchase College and both an M.S. in Biochemistry and an M.B.A. in Finance from NYU. Mr. Richard is also on the board of Bioclin Therapeutics, Inc. and was formerly on the Board of Merus N.V. as an observer.
Jeanmarie Guenot, Ph.D.
President & Chief Executive Officer
Jeanmarie Guenot, Ph.D. has 25 years of experience in the pharmaceutical and biotechnology industries. She has worked at both public and private companies, and across research and development, corporate development and venture capital. Among her achievements are several noteworthy bio-pharma mergers/acquisitions and licensing deals. Her experience spans small molecules and proteins and a variety of therapeutic areas including inflammation, autoimmune disease, oncology, cardiology, metabolic diseases, ophthalmology and neurology. She has more recently focused in immuno-oncology and specifically, in T cell engagement and bi-specific antibody drug development. Since 2013, Dr. Guenot has been the President & CEO of Amphivena Therapeutics, Inc., a clinical stage company developing a novel CD33 x CD3 bispecific antibody therapeutic for acute myeloid leukemia and myelodysplastic syndrome. She also co-founded Harpoon Therapeutics in 2015 and was its founding CEO and President. She co-founded Maverick Therapeutics in 2016, a spinout of Harpoon, and executed a build-to-buy deal with Takeda in January 2017 which comprised $125 million in funding including R&D support, option fee and equity investment.
Prior to her current role, Dr. Guenot co- founded, built and ran SKS Ocular, a start-up ophthalmic company incubator, focused on dry AMD, sustained release ocular drug delivery technologies and therapeutics for glaucoma, macular degeneration and ocular inflammation. She was a business advisor for Hoffmann-La Roche in Basel and Shanghai, and she was Vice President of Corporate & Business Development at PDL BioPharma, where she led licensing, mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios. She led and negotiated the Biogen Idec-PDL 50:50 co-development and co-commercialization strategic collaboration, which involved three Phase 2 cancer and autoimmune disease drug candidates. This $800 M transaction included a $100 M equity investment in PDL and a therapeutic candidate with indications split between Biogen Idec/PDL and Hoffmann-La Roche. She also licensed the ophthalmic indication for the oncology drug to Ophthotech. She has portfolio, project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases, neurology and ophthalmic diseases.
Dr. Guenot started her business career at Atlas Venture, where she managed venture capital investments and built life science companies. She started her scientific career as a principal scientist in Preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic diseases, inflammation, autoimmune diseases and oncology. Dr. Guenot trained in physical and medicinal chemistry, with a focus in quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. She earned her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.